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Background: DNA repair by homologous recombination (HR) is critical to maintain genomic integrity.
Results:Loss of inositol pyrophosphate synthesis by inositol hexakisphosphate kinase 1 (IP6K1) impairsHR inmammalian cells,
leading to increased cell death.
Conclusion:We report a new player in mammalian HR repair.
Significance: As cancer chemotherapeutics act by causing DNA damage, IP6K1 inhibition may provide a novel route to
supplement chemotherapy.
Inositol pyrophosphates, such as diphosphoinositol pentaki-
sphosphate (IP7), are water-soluble inositol phosphates that
contain high energy diphosphate moieties on the inositol ring.
Inositol hexakisphosphate kinase 1 (IP6K1) participates in ino-
sitol pyrophosphate synthesis, converting inositol hexakisphos-
phate (IP6) to IP7. In the present study, we show that mouse
embryonic fibroblasts (MEFs) lacking IP6K1 exhibit impaired
DNA damage repair via homologous recombination (HR).
IP6K1 knock-out MEFs show decreased viability and reduced
recovery after induction of DNA damage by the replication
stress inducer, hydroxyurea, or the radiomimetic antibiotic,
neocarzinostatin. Cells lacking IP6K1 arrest after genotoxic
stress, andmarkers associated with DNA repair are recruited to
DNAdamage sites, indicating thatHR repair is initiated in these
cells. However, repair does not proceed to completion because
these markers persist as nuclear foci long after drug removal. A
fraction of IP6K1-deficient MEFs continues to proliferate
despite the persistence of DNA damage, rendering the cells
more susceptible to chromosomal aberrations. Expression of
catalytically active but not inactive IP6K1 can restore the repair
process in knock-out MEFs, implying that inositol pyrophos-
phates are required for HR-mediated repair. Our study there-
fore highlights inositol pyrophosphates as novel small molecule
regulators of HR signaling in mammals.
Inositol pyrophosphates are water-soluble derivatives of ino-
sitol that contain pyrophosphate or diphosphate moieties in
addition to monophosphates. The best characterized inositol
pyrophosphates are IP7 4 (diphosphoinositol pentakisphos-
phate or PP-IP5) and IP8 (bisdiphosphoinositol tetrakisphos-
phate or (PP)2-IP4) (1–3). These energy-rich small molecules
are present in all eukaryotic cells and are involved in a wide
range of cellular functions including apoptosis, telomere length
maintenance, osmoregulation, phosphate homeostasis, and
insulin exocytosis. IP7 and IP8 are synthesized from inositol
hexakisphosphate (IP6) via two complementary pathways (3, 4).
IP6 kinases (IP6Ks) transfer a phosphate group fromATP to IP6
to synthesize an isomer of IP7 with a diphosphate moiety at the
5 position. 5-IP7 is further phosphorylated by VIP1 to generate
a second diphosphate at the 1 position, yielding IP8 (1,5(PP)2-
IP4) (5). In an alternate pathway, VIP1 generates 1-IP7 from IP6,
which is then converted to IP8 by IP6Ks. Mammals have three
isoforms of IP6 kinase, IP6K1, IP6K2, and IP6K3, whereas Sac-
charomyces cerevisiae have a single IP6 kinase, KCS1 (6, 7).
Inositol pyrophosphates regulate protein function via two
molecular mechanisms, protein binding and protein pyrophos-
phorylation (2, 3). A particular inositol pyrophosphate may
selectively bind a protein and regulate its function. Examples
include the specific binding of 1-IP7 to PHO81, a cyclin-depen-
dent kinase inhibitor that regulates phosphate homeostasis in
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yeast (8), and 5-IP7 binding to the pleckstrin homology domain
of Akt (9, 10). Any inositol pyrophosphate may act as a phos-
phate donor in the presence of divalent metal ions, transferring
its -phosphate to a prephosphorylated serine residue to form
pyrophosphoserine (11, 12). Recent studies have revealed that
IP7-mediated protein pyrophosphorylation regulates vesicle
trafficking in mammals and glycolysis in yeast (13, 14).
IP6 kinases have been shown to be involved in the mainte-
nance of genomic integrity in yeast. S. cerevisiae strains lacking
KCS1 have longer telomeres than wild type strains (15, 16), and
inositol pyrophosphates support DNA hyperrecombination in
yeast containing a mutant form of protein kinase C (17, 18).
Genomic insults that occur in mitotic cells due to stalled or
collapsed replication forks or exposure to DNA damage agents
(19) induce DNA double-strand breaks (DSBs) and trigger
repair via homologous recombination (HR). A complex cell sig-
naling cascade coordinates DNA repair with progression
through cell cycle checkpoints (20). Mitotic cells with impaired
HRmay stop dividing and undergo cell death or may overcome
cell cycle checkpoints and accumulatemutations in their DNA,
leading to cancer.
In the HR signaling network, we now report a new player,
IP6K1.Here, we examineDNAdamage repair inmouse embry-
onic fibroblasts (MEFs) derived from IP6K1 knock-out mice.
Our data reveal that inositol pyrophosphates synthesized by
IP6K1 are essential for HR-mediated DNA repair. We observe
that MEFs lacking IP6K1 can initiate HR but fail to complete
the process, resulting in cell death or accumulation of chromo-
somal aberrations. IP6K1 is therefore required to protect
genomic integrity in mammalian cells.
EXPERIMENTAL PROCEDURES
Cell Lines—Single cell-derived wild type (IP6K1/) and
IP6K1 knock-out (IP6K1/) MEF cell lines were generated
from IP6K1/ and IP6K1/ embryo-derived immortalized
fibroblasts (21) by dilution plating. A catalytically inactive form
ofmouse IP6K1 (K226A/S334A)was generated by site-directed
mutagenesis. IP6K1/ MEFs expressing active or inactive
forms of IP6K1 were generated by retroviral transduction.
cDNA encoding Myc-tagged active and inactive IP6K1 were
cloned into pCX4Neo plasmid (22) and co-transfected with
VSV-G- and VSV-GP-encoding plasmids into PlatE cells (Cell
Biolabs) using PolyFect reagent (Qiagen). Retroviral particles
derived from these cells were used to infect IP6K1/ MEFs,
and following selection in G418 (400 g/ml) for 7 days, single
cell-derived lines were generated by dilution plating. Cell lines
weremaintained in completeDMEM (HyClone) supplemented
with 10% (v/v) fetal bovine serum (FBS, Invitrogen), Pen-Strep
(100 g/ml streptomycin, 100 units/ml penicillin; Invitrogen),
with or without G418 (200g/ml). Cells were grown at 37 °C in
an incubator containing 5% CO2.
Antibodies and Reagents—Primary antibodies for immuno-
fluorescence, Western blot, and FACS analyses were obtained
from the following sources: rabbit anti-BLM (A310-167A,
Bethyl Laboratories); DR1034, (Calbiochem); rabbit anti-Rad51
(PC130, Calbiochem); rabbit anti-H2AX (ab2893, Abcam); rab-
bit anti-H3S10 (ab5176, Abcam); rabbit anti-IP6K1 (HPA040825,
Sigma-Aldrich); and mouse anti-GAPDH (G8795, Sigma-Al-
drich). DNA-damaging agents used for this study were
obtained from the following sources: hydroxyurea (HU,H8627,
Sigma-Aldrich); neocarzinostatin (NCS, N9162, Sigma-Al-
drich); and mitomycin C (M0503, Sigma-Aldrich). All other
reagents, unless otherwise stated, were procured from
Sigma-Aldrich.
Cell Survival Assay—MEFs were seeded in 24-well plates at a
density of 30,000 cells/well and allowed to growovernight. Cells
were treated with HU or NCS at the indicated concentrations
for 12 h, spent medium containing drug was removed, and cells
were washed with PBS. Cells were then incubated for different
lengths of time in normal medium to allow them to recover
from genotoxic stress. Cell viability was analyzed byMTT assay
at each time point. Absorbance values at 570 nm were deter-
mined using a microplate reader (BioTek Instruments). Cell
survival was expressed as a -fold change in cell population over
viable cells present immediately after drug treatment for 12 h.
Data were analyzed using GraphPad Prism 5.
Cell Cycle Analysis—Cells were grown in 35-mm dishes at a
density of 2  105 cells/dish. At 60% confluence, cells were
treated with HU or NCS for 12 h. After treatment, medium
containing drug was removed, and normal medium was added
for recovery of the cells from genotoxic stress for different
lengths of time. Cells were fixed in 70% ethanol overnight at
20 °C and stained with propidium iodide (PI; 20 g/ml in PBS
containing 0.1%TritonX-100 and 0.2mg/mlRNaseA) for 30min
at 37 °C. Alternatively, 5-ethynyl-2-deoxyuridine (EdU) labeling
and cell cycle analysis were conducted using the Click-iT cell
proliferation assay kit (C35002, Invitrogen), as per themanufac-
turer’s instructions. Cells were analyzed by flow cytometry (FAC-
SAria, BD Biosciences). Data analysis to determine the stages
of the cell cycle was performed using FlowJo (for PI-labeled
cells) or FACSDiva (BDBiosciences; for EdU-labeled cells), and
results were plotted using GraphPad Prism 5.
Cell Viability Assay by PI Staining—MEFs were treated with
HU for 12 h and allowed to recover for different lengths of time.
Cells were harvested, washed with PBS, and stained with PI (2
g/ml in PBS) for 2 min at room temperature. Under these
conditions, live cells exclude dye, and only nonviable cells are
stained. Live versus dead cells were analyzed by flow cytometry
(Accuri C6, BD Biosciences).
Immunofluorescence—Localization of the DNA damage
response proteins, phosphorylated histone H2AX (H2AX),
RAD51, and BLM, and the mitotic marker, H3S10 (histone H3
phosphorylated on Ser-10) upon genotoxic stress was analyzed
by immunofluorescence following hypotonic lysis. Briefly, cells
were seeded on coverslips in 12-well plates at a cell density of
30,000–40,000 cells/well and incubated overnight. Cells were
treatedwithHUorNCS for 12 h, and immunofluorescence was
carried out as described earlier (23). Images were acquired by
confocal fluorescence microscopy (Zeiss LSM 510 META).
Nuclear foci were visualized using LSM Browser software, by
linearly changing the contrast uniformly across all images, for
background correction. 70–100 cells were analyzed per exper-
iment to count nuclear foci.
TUNELAssay—MEFswere seeded in 35-mmdishes at a den-
sity of 2 105 cells/dish. At 60% confluence, cells were treated
with HU for 12 h and allowed to recover for different lengths of
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time. Cells were harvested and fixed in 70% ice-cold ethanol
overnight at20 °C. TUNEL assay to detect DNA damage was
conducted using an APO-BrdU TUNEL assay kit (A35127,
Invitrogen), as per the manufacturer’s instructions. Cells were
analyzed by flow cytometry (FACSAria, BD Biosciences). Via-
ble cells were analyzed for the presence of DNA damage by
excluding the hypodiploid (sub-G0/G1) population, using the
FACSDiva software (BDBiosciences).Median fluorescence val-
ues of the treated cells were plotted as a -fold difference over
untreated controls, using GraphPad Prism 5.
Cytogenetic Analysis—MEFs were treated with mitomycin C
(300 nM) for 12 h, washed, and treated with colcemid (0.1 g/ml)
for 4 h. Cells were harvested, subjected to hypotonic swelling in
prewarmed 0.075 M KCl for 15 min at 37 °C, and fixed in three
changes of 3:1 methanol/glacial acetic acid at room temperature
for 10 min each. Cells resuspended in fixative were dropped onto
humidified, clean, and chilled glass slides. Slides were dried and
stained with 3% Giemsa in phosphate buffer (pH 6.8). Individual
metaphase spreads were analyzed using bright field microscopy
(Zeiss Axio Scope) and photographed, and structural chromo-
somal aberrations (chromatid breaks and triradial and quadrira-
dial chromosomes) were scoredmanually.
IP6K2 Knockdown by shRNA—Plasmids encoding either a
nontargeting shRNA(Sigma-AldrichSHC016)or shRNAdirected
against mouse IP6K2 (Sigma-Aldrich, TRCN0000202175 or
TRCN0000202065)were co-transfectedwithVSV-G- andVSV-
GP-encoding plasmids into the Phoenix amphotropic packag-
ing cell line, using PolyFect reagent (Qiagen), and incubated at
37 °C and 5% CO2 for virion formation. After 48 h, supernatant
was collected and filtered through a 0.45-m syringe filter unit.
Lentiviral particles carrying either nontargeting shRNAor both
IP6K2-directed shRNAconstructs were used to infectMEFs for
48 h. At the 36th h, cells were treated withHU for 12 h followed
by recovery for 6 h, and immunofluorescencewas carried out as
described above. Immunoblotting with an IP6K antibody in
IP6K1/ MEFs revealed a 40% knockdown of IP6K2 expres-
sion in cells transduced with IP6K2-targeting shRNA when
compared with nontargeting shRNA (data not shown).
RESULTS
Reduced Viability of IP6K1 Knock-out MEFs after Induction
of DSBs—Treatment with hydroxyurea (HU), a ribonucleotide
reductase inhibitor, leads to replication stress and arrests cells
at the G1/S boundary of the cell cycle (24). Prolonged replica-
tion stalling by HU treatment generates one-ended DSBs and
initiates DNA repair via HR. The radiomimetic antibiotic NCS
directly causes double-strand breaks in DNA, triggering HR-
mediated repair (19). MEFs derived from IP6K1 knock-out
embryos and their wild type litter mates have been used to
examine the cellular functions of IP6K1 (9, 13, 14, 21).
IP6K1/ and IP6K1/ MEFs were treated with a sublethal
dose of HU or NCS for 12 h, and cell viability was determined
after a recovery period of 24 h. IP6K1/ cells display a more
pronounced drop in viability after HU removal when compared
with IP6K1/MEFs (Fig. 1A). After recovery fromNCS treat-
ment, both IP6K1/ and IP6K1/MEFs proliferate, but the
extent of proliferation is lower in knock-out MEFs (Fig. 1B).
Tomonitor cell cycle progression ofMEFs subjected to geno-
toxic stress, we used flow cytometry analysis to measure the
extent of arrest and release during a 12-h period after drug
removal. IP6K1/ cells arrest at the G1/S boundary to the
same extent as IP6K1/ cells, indicating that checkpoint acti-
vation subsequent to DNA damage is intact in the absence of
IP6K1 (Fig. 2A). However, fewer IP6K1/ cells enter the S
phase after HU removal, suggesting their inability to recover
fromDNA damage (Fig. 2,A and B). Conversely, a higher num-
ber of knock-outMEFs are present in the hypodiploid (sub-G0/
G1) population after a 12-h recovery period (Fig. 2, A and C).
We confirmed that this population represents nonviable cells
bymeasuring propidium iodide uptake followingHU treatment
and recovery (Fig. 2D). Upon treatment with NCS, IP6K1/
and IP6K1/ MEFs arrest similarly at the G2/M boundary
(Fig. 2E). However, a lower fraction of IP6K1/MEFs recovers
from the arrest and is present in the G0/G1 phase 12 and 24 h
after drug removal (Fig. 2F), and there is a concomitant increase
in the number of hypodiploid IP6K1/ cells (Fig. 2G).
Together, these data reveal that subsequent to DNA damage,
IP6K1 knock-out cells show reduced recovery and increased
cell death when compared with wild type cells.
HR Is Initiated but Stalls in IP6K1 Knock-out MEFs—Loss of
cell viability during recovery from genotoxic stress may be
attributed to a defect in DNA repair. The DNA damage
response may be monitored by the recruitment of DNA repair
markers to the site of damage. An early event following HU-
induced replication stress is the accumulation of H2AX at the
site of DNA damage (25), and the clearance of nuclear H2AX
foci reflects successful DNA repair. We monitored nuclear
H2AX levels inMEFs immediately after HU treatment and 6 h
after drug removal, the time at which S phase entry in wild type
MEFs is maximal, and DNA damage is expected to be repaired.
IP6K1/ MEFs display a significantly higher number of
H2AX foci followingHU treatment (Fig. 3,A andB). Thismay
reflect accumulation of greater DNA damage in knock-out
FIGURE 1. Impaired recovery of IP6K1/ MEFs following DNA damage.
A andB, cell viabilitymeasurementbyMTTassay following treatmentwithHU
(0.5 mM) (A) or NCS (0.25 g/ml) (B) for 12 h and recovery after drug removal
for 24 h. Data aremean S.E. from three independent experiments. p values
are from a two-tailed Student’s t test (**, p 0.01).
IP6K1 in Homologous Recombination Repair
3314 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 288•NUMBER 5•FEBRUARY 1, 2013
 by guest on A
ugust 30, 2017
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
MEFs during the period of drug treatment. Although H2AX
foci are nearly undetectable in IP6K1/ MEFs after recovery
from HU treatment, indicating repair of damaged DNA, they
continue to persist at high levels in IP6K1/MEFs, suggesting
that these cells have defective or delayed DNA damage repair.
RAD51 is recruited to the sites of DSBs in a H2AX-depen-
dent process and participates in the early steps of HR, homol-
ogy search and strand invasion (26). BLM is a RecQ family heli-
case that participates in DNA damage sensing at an early stage
and in Holliday junction resolution toward the end of HR (27).
We used these proteins as surrogate markers to track initiation
and completion of HR in HU-treated MEFs. As with H2AX,
more RAD51 and BLM foci are observed in IP6K1/ MEFs
immediately afterHU treatment (Fig. 3,C–F). These foci persist
6 h after HU removal in knock-out, but not in wild type MEFs.
Interestingly, we observed a variation in the average number of
foci marked by H2AX, RAD51, and BLM antibodies after a
12-h HU treatment of wild type MEFs. This could reflect a
difference in sensitivity between these antibodies or a differ-
ence in the temporal association of the respective proteins at
the sites of damage. We also noted experimental variation in
foci counts using the same antibody, but the trend of persistent
DNA damage markers in IP6K1/ MEFs was conserved
throughout. Upon treatment with NCS, BLM accumulation is
FIGURE 2. Cell cycle progression of MEFs in response to DNA damage. A, cell cycle profiles of MEFs following HU (0.2 mM) treatment and recovery for the
indicated times. Dot plots representative of three independent experiments show DNA content on the x axis against EdU incorporation on the y axis; boxes
mark cells in the sub-G0/G1 (yellow), G0/G1 (blue), S (green), and G2/M (magenta) phases of the cell cycle. Percentages of cells present in sub-G0/G1 and S
populations are indicated. Alexa488, Alexa Fluor 488. B and C, cell cycle analysis to monitor recovery at the indicated times after HU (0.2 mM) treatment by
measuring entry into S phase (B) and cell death (sub-G0/G1 (G0/G1) population) (C). Data aremean S.E. from four independent experiments.D, cell viability
assay by PI staining of MEFs following HU (0.2mM) treatment and recovery for the indicated times. Dead cells stained with PI are expressed as a percentage of
total cell count. Data are mean range from two independent experiments. E, flow cytometry analysis of PI-stained MEFs prior to or after NCS (0.25 g/ml)
treatment. Histograms indicate a normal cell cycle profile in untreated cells, and arrest at the G2/M boundary in NCS-treated cells. Data are representative of
three independent experiments. FandG, cell cycle analysis tomonitor recovery at the indicated timesafterNCS (0.25g/ml) treatmentbymeasuringentry into
the G0/G1 phase (F) and cell death (sub-G0/G1 population) (G). Data are representative of three independent experiments. p values are from a two-tailed
Student’s t test (*, p 0.05, **, p 0.01, ***, p 0.001).
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similar in IP6K1/ and IP6K1/ MEFs, but after recovery,
BLM foci persist in knock-out cells and are back to base-line
levels in wild type cells (Fig. 3, G and H). Thus far, our data
indicate that the process of DNA repair via HR is successfully
initiated in the absence of IP6K1, but cannot be completed,
leading to increased cell death.
IP6K1 Loss Increases Chromosomal Damage Susceptibility—
Wewondered whether the persistence of RAD51 and BLM foci
in IP6K1/ cells 6 h after recovery fromHU treatment reflects
the absence of HR-mediated DNA repair or whether repair is
delayed, but eventually complete. We therefore examined
MEFs treated with HU for nuclear BLM foci at longer time
periods of recovery. A high number of BLM foci continue to
persist 8 and 10 h following HU removal in IP6K1/ MEFs
(Fig. 4, A and B). Persistence of BLM foci may be indicative of
defective DNA repair, but could also reflect incomplete disso-
lution of DNA repair complexes despite the completion of HR.
We therefore monitored DNA repair subsequent to HU
removal by conducting a TUNEL assay to measure DNA dam-
age. Although the level of TUNEL staining falls down to the
FIGURE 3. Recruitment of HR markers following DNA damage. Immunofluorescence of DNA repair markers in nuclei of MEFs after drug treatment and
recovery for the indicated times was measured. A, H2AX foci after HU (0.5 mM) treatment. B, quantitation of A; data (mean S.E. n 150) are representative
of two experiments. C, RAD51 foci after HU (0.5 mM) treatment.D, quantitation of C; data (mean S.E. n 130) are representative of two experiments. E, BLM
foci after HU (0.5 mM) treatment. F, quantitation of E; data (mean  S.E. n  80) are representative of two experiments. G, BLM foci after NCS (0.25 g/ml)
treatment. H, quantitation of G; (mean  S.E. n  70). Images compiled from different regions of a single micrograph are juxtaposed where required and
separated by awhite line. p values are from a two-tailed Student’s t test (***, p 0.001).
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base-line 12 h after drug removal in IP6K1/ MEFs, DNA
damage continues to persist in IP6K1/ MEFs (Fig. 4C).
Increased cell death at 9 and 12h afterHU removal in IP6K1/
MEFs (Fig. 2, C andD) is thus attributable to the persistence of
DNA damage in these cells.
To determine whether IP6K1/ MEFs cross the G2/M
checkpoint and enter mitosis despite the persistence of dam-
agedDNA,we stained cells for the presence of histoneH3phos-
phorylation at Ser-10, amarker for the initiation ofmitosis (28).
An increase in the mitotic population in IP6K1/ MEFs fol-
lows the timeline of DNA repair (Fig. 4,D and E). IP6K1 knock-
out MEFs display delayed entry into mitosis 10 h after HU
removal (Fig. 4D) despite the persistence of DNA damage (Fig.
4C). Indeed, when proliferation of MEFs is monitored up to 4
days after HU removal, there is an eventual increase in viable
IP6K1/MEFs, although it is still lower than IP6K1/MEFs
(Fig. 4F). Proliferation of cells by continuing DNA replication
without repairing DNA damage can result in the accumulation
of chromosomal lesions (29). Defects in HR can lead to
increased sensitivity to mitomycin C, a drug that induces DNA
FIGURE 4. Persistence of DNA damage in IP6K1 knock-outMEFs. A, BLM foci formation in nuclei after HU (12 h, 0.5 mM) treatment of MEFs and recovery for
the indicated times. B, quantitation of A; data (mean S.E. n 100) are representative of two experiments. C, detection of DNA DSBs by TUNEL staining and
flow cytometry analysis after HU (12 h, 0.5 mM) treatment of MEFs and recovery for the indicated times; bars represent mean  range of two independent
experiments.D, quantitationof histoneH3Ser-10phosphorylation inMEFs afterHU (12h, 0.5mM) treatment and recovery for the indicated times; bars indicate
thepercentageof positive cells (n140; representativeof twoexperiments). E, representative immunofluorescence images forD. F, cell viabilitymeasurement
byMTT assay following treatmentwith HU (12 h, 0.5mM) and recovery for the indicated times; bars representmean range of two independent experiments.
G, representative images showing chromosomal lesions (marked by arrows) found in metaphase spreads fromMEFs treated with mitomycin C (12 h, 300 nM).
H, quantitationofG; data (mean S.E.n 41) are representative of twoexperiments.p values are froma two-tailed Student’s t test (**,p 0.01, ***,p 0.001).
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interstrand cross-links, blocking DNA replication (19). Analy-
sis ofmetaphase spreads followingmitomycinC treatmentmay
therefore be used to probe defects in DNA repair (30). When
treated with mitomycin C, IP6K1/ MEFs show more chro-
mosomal abnormalities, such as triradial and quadriradial
chromosomes and chromatid breaks, when compared with
IP6K1/MEFs (Fig. 4, G and H).
Inositol Pyrophosphate Synthesis Is Required for HR-medi-
ated DNA Repair—Although the primary role of IP6 kinases is
the synthesis of inositol pyrophosphates, these enzymes are
also known to regulate cell function independent of their cata-
lytic activity (31). To determine whether the role of IP6K1 in
HR is dependent upon its inositol pyrophosphate synthesis
activity, we stably expressed active and catalytically inactive
forms of IP6K1 in IP6K1/ MEFs (Fig. 5A). IP6K1/ MEFs
expressing active IP6K1 displayed higher levels of IP7 when
compared with their counterparts that express inactive IP6K1
(Fig. 5B). Cell viability after recovery from HU treatment was
restored by expressing active IP6K1 in IP6K1/ MEFs, but
cells expressing inactive IP6K1 show reduced viability,mimick-
ing the phenotype of parent IP6K1/ cells (Fig. 5C). A similar
phenomenonwas observed on analysis of cell cycle progression
following HU treatment. IP6K1/ cells expressing active
IP6K1 enter the S phase and recover from HU treatment,
whereas cells expressing inactive IP6K1 demonstrate reduced
entry into S phase and a higher population of hypodiploid cells
(Fig. 5D). HR repair after HU treatment was examined in these
cells by monitoring BLM foci accumulation in nuclei (Fig. 5, E
and F). BLM foci persist after recovery from HU treatment in
cells expressing inactive IP6K1, but the foci are reduced in cells
expressing active IP6K1. When treated with mitomycin C,
IP6K1/MEFs expressing inactive IP6K1 accumulate a higher
number of chromosomal abnormalities when compared with
MEFs expressing active IP6K1 (Fig. 5G). Taken together, these
data strongly indicate that inositol pyrophosphate synthesis by
IP6K1 is essential for HR-mediated repair of damaged DNA.
Most mammalian cells are known to express two isoforms of
IP6 kinase, IP6K1 and IP6K2. IP6K1 knock-outMEFs display an
70% reduction in IP7 levels (21), and IP6K2 knock-out MEFs
reduce IP7 by 38% (32), implying that IP7 production inMEFs is
dependent on both IP6 kinase isoforms.We wondered whether
the marginal levels of repair observed in IP6K1/ MEFs fol-
lowing HU treatment are due to IP7 production by IP6K2.
Although wild type MEFs expressing a nontargeting shRNA
show recovery fromHU treatment, MEFs targeted with IP6K2-
specific shRNAdisplay reduced recovery, as reflected by persis-
tent nuclear staining with BLM (Fig. 5, H and I). These data
suggest that there is some redundancy in the function of IP6K1
and IP6K2 with regard to the synthesis of IP7 involved in HR-
mediated DNA repair. Expression of a nontargeting control
shRNA in IP6K1/ MEFs abolished any recovery following
HU treatment (data not shown), perhaps due to the added
stress of viral transduction coupled with DNA damage, making
it difficult to interpret the effects of simultaneously reducing
IP6K1 and IP6K2 on DNA repair.
DISCUSSION
Our study identifies IP6K1 as a key player in HR-mediated
DNA repair. Specifically, we have shown that cells lacking
IP6K1 are able to initiate HR after being subjected to genotoxic
stress, but fail to repair damagedDNA. As a result, many IP6K1
knock-out cells undergo death, and those that survive accumu-
late chromosomal lesions. Functional down-regulation ofmany
proteins involved inHR leads to reduced recruitment of theHR
marker RAD51 to the sites ofDNAdamage (33, 34). In contrast,
IP6K1 knock-out cells accumulate a higher number of H2AX
and RAD51 foci, which may reflect greater DNA damage, but
nonetheless indicate that HR initiation is normal in these cells.
Therefore, IP6K1 is a rare factor required for downstream pro-
cesses duringHR, such as strand exchange, DNA synthesis, and
Holliday junction resolution.
Our results may be examined in the context of the reported
pro-recombinogenic effect of the yeast IP6 kinase, KCS1 (17,
18). kcs1	 yeast show reduced survival after treatment with
phleomycin, which causes DNA DSBs (35). Although yeast
have a single IP6 kinase, mammals express three IP6K isoforms.
IP6K3 is expressed primarily in the brain and not found inmost
peripheral tissues (7). Although IP6K1 and IP6K2 are expressed
inmost cells and tissues, they have been shown to participate in
nonoverlapping cellular functions. For example, insulin release
in pancreatic  cells is dependent on IP7 synthesis by IP6K1
(36), whereas IP6K2 is a key pro-apoptotic regulator, even in
cell types that possess both isoforms (37). Mouse knock-out
models for these enzymes also display divergent phenotypes.
IP6K1 knock-out male mice are infertile, lacking mature sper-
matozoa, and have reduced serum insulin levels (21), whereas
IP6K2 knock-out males are fertile and display normal serum
insulin (32). When challenged with an oral carcinogen, IP6K2
knock-outmice developed aerodigestive tract tumors (32). This
phenotype was attributed to a critical role for IP6K2 in apopto-
sis. The functional redundancy, if any, between IP6K1 and
IP6K2 in the context of the whole organism is not clear. There-
fore, challenging IP6K1 knock-out mice with a carcinogen may
clarify whether IP6K1 and IP6K2 play redundant or nonover-
FIGURE5. Inositolpyrophosphate synthesisby IP6K1 is required forDNArepair.A, immunoblottingof cell extracts fromMEFsof indicatedgenotypes,with
IP6K1 and GAPDH antibodies. B, IP6 and IP7 levels in IP6K1
/MEFs rescued with active and inactive forms of IP6K1 was measured by [3H]inositol labeling as
described previously (21). Soluble inositol phosphate counts were normalized to total lipid inositol count and plotted using GraphPad Prism 5. C, cell viability
measurement byMTT assay after treatment ofMEFswith HU (12 h, 0.5mM) and recovery for the indicated times. Data aremean S.E. from three independent
experiments.D, cell cycle profiles of MEFs following HU (0.2mM) treatment and recovery for the indicated times. Dot plots representative of two independent
experiments showDNAcontent on the x axis against EdU incorporationon the y axis;boxesmark cells in the sub-G0/G1 (yellow), G0/G1 (blue), S (green), andG2/M
(magenta) phases of the cell cycle. Percentages of cells present in sub-G0/G1 andSpopulations are indicated.Alexa488, Alexa Fluor 488. E, immunofluorescence
of BLM foci formation in nuclei after HU (0.5 mM) treatment of MEFs and recovery for the indicated times. Images compiled from different regions of a single
micrograph are juxtaposed and separated by awhite line. F, quantitation of E; data (mean S.E. n 200) are compiled from two experiments. G, quantitation
of chromosomal lesions inmetaphase spreads fromMEFs after treatmentwithmitomycin C (12 h, 300 nM) (mean S.E. n 28).H, BLM foci formation in nuclei
after HU (12 h, 0.5 mM) treatment of wild type MEFs transduced with lentivirus encoding either nontargeting shRNA or shRNA directed against IP6K2, and
recovery for the indicated times. I, quantitation of H; data (mean S.E. n 200) are compiled from two experiments. p values are from a two-tailed Student’s
t test (**, p 0.01, ***, p 0.001).
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lapping roles in maintaining genome integrity. Such experi-
ments are currently underway.
At a mechanistic level, we observe that inositol pyrophos-
phate synthesis by IP6K1 is essential for the completion of HR,
as evidenced by the lack of repair in IP6K1/MEFs expressing
catalytically inactive IP6K1. Inositol pyrophosphates may reg-
ulate the later stages of HR by binding or pyrophosphorylating
one or more proteins involved in these processes. We are
currently examining these possibilities using radiolabeled
IP7 along with purified proteins in IP7 binding and pyrophos-
phorylation assays. Interestingly, we have identified HR pro-
teins that are potential targets of IP7, based on the presence of
acidic serine sequence motifs that define sites for serine
pyrophosphorylation.
The reported nuclear localization of IP6K1 supports our
observations regarding its critical role in DNA repair (7). Our
work also contributes to the body of information available on
nuclear roles of other higher inositol phosphates (4). Previous
studies have demonstrated a role for IP4 and IP5 in chromatin
remodeling (38, 39). IP6 is involved in mRNA export (40–42)
and DNA repair via nonhomologous end joining (43).
In summary, our data reveal a role for inositol pyrophos-
phates synthesized by IP6K1 in HR-mediated repair of DSBs in
mammalian cells. Inositol pyrophosphates are not involved in
cell cycle checkpoint activation orHR initiation, but participate
in the successful completion of HR. The absence of IP6K1 ren-
ders cells more susceptible to DNA damage agents. Because
many cancer therapeutic strategies involve DNA replication
stress, which leads to DSBs (44), we speculate that inhibition of
IP6K1 activity may be used to supplement chemotherapy. Fur-
therwork is required to determine the effects of reducing IP6K1
activity on the outcome of cancer chemotherapeutics.
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